Abstract
l-Deprenyl (selegiline) is used in the treatment of Parkinson’s disease and has been proposed as an aid for cigarette smoking cessation and a treatment for psychostimulant abuse. l-Deprenyl is metabolized in the body to l-methamphetamine and l-amphetamine, suggesting that it may have abuse potential. The current study assessed whether l-deprenyl or its isomer would maintain drug-seeking behavior on a second-order schedule and whether l-deprenyl would alter drug-seeking behavior maintained by d-amphetamine if given as a pretreatment. Squirrel monkeys learned to respond on a second-order schedule of reinforcement, where every tenth response was followed by a brief light flash, and the first brief light flash after 30 min was paired with intravenous (i.v.) injection of d-amphetamine (0.56 mg/kg), administered over a 2-min period at the end of the session. When responding was stable, saline or different i.v. doses of d-amphetamine (0.3–1.0 mg/kg), l-deprenyl (0.1–10.0 mg/kg), and d-deprenyl (0.1–3.0 mg/kg) were substituted for 10 days each. Subsequently, monkeys were pretreated with 0.3 or 1.0 mg/kg l-deprenyl intramuscularly 30 min prior to d-amphetamine baseline sessions. d-Amphetamine maintained high rates of drug-seeking behavior on the second-order schedule. d-Deprenyl maintained high rates of drug-seeking behavior similar to d-amphetamine. l-Deprenyl maintained lower rates of responding that were not significantly above saline substitution levels. Pretreatment with l-deprenyl failed to alter drug-seeking behavior maintained by d-amphetamine. These results indicate that d-deprenyl, but not l-deprenyl, may have abuse potential. Under conditions where drug-seeking and drug-taking behaviors are actively maintained by d-amphetamine, l-deprenyl, at doses that specifically inhibit type B monoamine oxidase, may not be effective as a treatment.
Similar content being viewed by others
References
Arnett CD, Fowler JS, MacGregor RR, Schlyer DJ, Wolf AP, Langstrom B, Halldin C (1987) Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl. J Neurochem 49:522–527
Bartzokis G, Beckson M, Newton T, Mandelkern M, Mintz J, Foster JA, Ling W, Bridge TP (1999) Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective rating of euphoria. Neuropsychopharmacology 20:582–590
Batke J, Gaal J (1993) Suicide inhibition of monoamine oxidases A and B by (−)-deprenyl. A computer-aided solution for determining inhibition specificity. Biochem Pharmacol 46:597–602
Bergman J, Yasar S, Winger GD (2001) Psychomotor stimulant effects of β-phenylethylamine in monkeys treated with MAO-B inhibitors. Psychopharmacology 159:21–30
Elsworth JD, Glover V, Reynolds GP (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology 57:33–38
Fang J, Yu PH (1994) Effect of l-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 33:763–768
Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schyler D, Wolf AP, Pappas N, Alexoff D, Shea C, Dorflinger E, Kruchowy L, Yoo K, Fazzini E, Patlak C (1994) Slow recovery of human brain MAO B after L-deprenyl (selegeline) withdrawal. Synapse 18:86–93
Garrick N, Murphy DL (1980) Species differences in the deamination of dopamine and other substances for monoamine in brain. Psychopharmacology 72:27–33
George TP, O’Malley SS (2004) Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25:42–48
George TP, Vessicchio JC, Angelo T, Jatlow PI, Kosten TR, O’Malley SS (2003) A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 53:136–143
Goldberg SR (1973) Comparable behavior maintained under fixed-ratio and second-order schedules of food presentation, cocaine injection or d-amphetamine injection in the squirrel monkey. J Pharmacol Exp Ther 186:18–30
Goldberg SR, Tang AH (1977) Behavior maintained under second-order schedules of intravenous morphine injection in squirrel and rhesus monkeys. Psychopharmacology 51:235–242
Goldberg SR, Morse WH, Goldberg DM (1976) Behavior maintained under a second-order schedule of intramuscular injection of morphine or cocaine in rhesus monkeys. J Pharmacol Exp Ther 199:278–286
Goldberg SR, Spealman RD, Kelleher RT (1979) Enhancement of drug-seeking behavior by environmental stimuli associated with cocaine or morphine injections. Neuropharmacology 18:1015–1017
Goldberg SR, Kelleher RT, Goldberg DM (1981) Fixed-ratio responding under second-order schedules of food presentation or cocaine injection. J Pharmacol Exp Ther 218:271–281
Goldberg SR, Schindler CW, Lamb RJ (1990) Second-order schedules and the analysis of human drug-seeking behavior. Drug Dev Res 20:217–229
Heikkila RE, Orlansky H, Mytilineou C, Cohen G (1975) Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 194:47–56
Heinonen EH, Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand 84(Suppl):44–59
Heinonen EH, Anttila MI, Lammintausta RAS (1994) Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56:742–749
Johanson C-E, Barrett JE (1993) The discriminative stimulus effects of cocaine in pigeons. J Pharmacol Exp Ther 267:1–8
Justinova Z, Goldberg SR, Heishman SJ, Tanda G (2005) Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 81:285–299
Katz JL (1979) A comparison of responding maintained under second-order schedules of intramuscular cocaine injection or food presentation in squirrel monkeys. J Exp Anal Behav 32:419–431
Kelleher RT (1966) Conditioned reinforcement in second-order schedules. J Exp Anal Behav 9:475–485
Koston TR, George TP, Kosten TA (2002) The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs 11:491–499
Lakshmana M, Rao BS, Dhingra NK, Ravikumar R, Govindaiah, Sudha S, Meti BL, Raju TR (1998) Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain. Neurochem Res 23 :1031–1037
Magyar K, Knoll J (1977) Selective inhibition of the “B” form of monoamine oxidase. Pol J Pharmacol Pharm 3:233–246
Magyar K, Palfi M, Tabi T, Lalasz H, Szende B, Szökö É (2004) Pharmacological aspects of (−)-deprenyl. Curr Med Chem 11:2017–2031
Mahmood I (1997) Clinical pharmacokinetics and pharmacodynamics of selegiline. Clin Pharmacokinet 33:91–102
Murphy DL, Redmond DE Jr, Garrick N, Baulu J (1979) Brain region differences and some characteristics of monoamine oxidase type A and B activities in the vervet monkey. Neurochem Res 4:53–62
National Research Council (2003) Guidelines for the care and use of mammals in neuroscience and behavioral research. National Academy Press, Washington, DC
Newton T, Kalechstein A, Beckson M, Bartzokis G, Bridge TP, Ling W (1999) Effects of selegiline pretreatment on response to experimental cocaine administration. Psychiatry Res 87:101–106
Ortmann R, Schaub M, Felner A, Lauber J, Christen P, Waldmeier PC (1984) Phenylethylamine-induced stereotypes in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology 84:22–27
Paterson IA, Juorio AV, Boulton AA (1990) 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 55:1827–1837
Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with l-deprenyl. J Neurochem 46:1359–1365
Schindler CW, Panlilio LV, Goldberg SR (2002) Second-order schedules of drug self-administration in animals. Psychopharmacology 163:327–344
Schindler CW, Gilman JP, Graczyk Z, Wang G, Gee WL (2003) Reduced cardiovascular effects of methamphetamine following treatment with selegiline. Drug Alcohol Depend 72:133–139
Schneider LS, Tariot PN, Goldstein B (1994) Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther 56:750–756
Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 168:3–20
Singer JD (1998) Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 24:323–355
Szökö É, Kalász H, Magyar K (1999) Metabolic transformation of deprenyl enantiomers in rats. Neurobiology 7:247–254
Timar J, Knoll B (1986) The effect of repeated administration of (−) deprenyl on the phenylethylamine-induced stereotypy in rats. Arch Int Pharmacodyn 279:50–60
Winger GD, Yasar S, Negus SS, Goldberg SR (1994) Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys. Clin Pharmacol Ther 56:774–780
Wise RA (1998) Drug-activation of brain reward pathways. Drug Alcohol Depend 51:13–22
Wu W-R, Zhu X-Z (1999) The amphetamine-like reinforcing effect and mechanism of l-deprenyl on conditioned place preference in mice. Eur J Pharmacol 364:1–6
Yasar S, Bergman J (1994) Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies. Clin Pharmacol Ther 56:763–768
Yasar S, Schindler CW, Thorndike EB, Szelenyi I, Goldberg SR (1993) Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative effects in rats. J Pharmacol Exp Ther 265:1–6
Yasar S, Schindler CW, Thorndike EB, Goldberg SR (1994) Evaluation of deprenyl for cocaine-like discriminative stimulus effects in rats. Eur J Pharmacol 259:243–250
Yasar S, Goldberg JP, Goldberg SR (1996) Are metabolites of l-deprenyl useful or harmful? Indications from preclinical research. J Neural Transm 48(Suppl):83–95
Yasar S, Gaal J, Justinova Z, Bergman J (2005) Discriminative stimulus and reinforcing effects of p-fluoro-l-deprenyl in monkeys. Psychopharmacology (DOI 10.1007/s00213-005-0063-y)
Yokel RA, Pickens R (1973) Self-administration of optical isomers of amphetamine and methamphetamine by rats. J Pharmacol Exp Ther 187:27–33
Youdim MBH, Finberg JPM (1994) Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors. Clin Pharmacol Ther 56:725–733
Acknowledgements
We thank Dr. Steven R. Goldberg for helpful suggestions on the conduct of this research and preparation of the manuscript. This research was supported by the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, and Chinoin Pharmaceutical and Chemical Works, Budapest, Hungary (now Sanofi-Synthelabo).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yasar, S., Gaál, J., Panlilio, L.V. et al. A comparison of drug-seeking behavior maintained by d-amphetamine, l-deprenyl (selegiline), and d-deprenyl under a second-order schedule in squirrel monkeys. Psychopharmacology 183, 413–421 (2006). https://doi.org/10.1007/s00213-005-0200-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-005-0200-7